Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
2010

Target enzyme mutations cause resistance to cancer drugs

publication Evidence: high

Author Information

Author(s): Uffe H. Olesen, Jakob G. Petersen, Antje Garten, Wieland Kiess, Jun Yoshino, Shin-Ichiro Imai, Mette K. Christensen, Peter Fristrup, Annemette V. Thougaard, Fredrik Björkling, Peter B. Jensen, Søren J. Nielsen, Maxwell Sehested

Primary Institution: Rigshospitalet, Copenhagen, Denmark

Hypothesis

Can mutations in the enzyme NAMPT lead to resistance against its inhibitors in cancer treatment?

Conclusion

Mutations in the NAMPT enzyme are primarily responsible for acquired resistance to NAMPT inhibitors in cancer cells.

Supporting Evidence

  • 4 out of 5 resistant cell lines had mutations in NAMPT.
  • Resistance was retained after 15 weeks without drug exposure.
  • Mutations were located in the binding site or dimer interface of NAMPT.

Takeaway

Some cancer cells can become resistant to drugs that target a specific enzyme, and this resistance is often due to changes in the enzyme itself.

Methodology

The study involved developing resistant cell lines, sequencing the NAMPT gene, and conducting in vitro and in vivo experiments to assess drug resistance.

Limitations

The study did not explore all potential mechanisms of resistance and focused primarily on NAMPT mutations.

Statistical Information

P-Value

0.005

Statistical Significance

p<0.005

Digital Object Identifier (DOI)

10.1186/1471-2407-10-677

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication